Dignity Hospice Medicare Approved Location: 557 Main Street, Chapmanville, West Virginia 25508 Phone: (304) 855-4764 |
News Archive
Spectrum Pharmaceuticals today announced that it has submitted an investigational new drug (IND) application to the U.S. Food & Drug Administration for SPI-014 (previously referred to as RENAZORB), a second-generation lanthanum-based nanoparticle phosphate binding agent, that has the potential to treat hyperphosphatemia in patients with Stage 5 chronic kidney disease, or end-stage renal disease (ESRD).
Older, sicker, high-risk patients who undergo one of the most common treatments for prostate cancer get better results in larger, busier hospitals, according to new research by Henry Ford Hospital.
A study in the June 1 issue of Cancer Research presents the first evidence that exposure to low doses of environmental estrogens during development of the prostate gland in the male fetus may result in a predisposition to prostate cancer later in life.
A team of researchers from Center for Biomedical Technology at Universidad Politécnica de Madrid has developed a pocket instrument capable of perceiving radio signals from 50 MHz to 6 MHz and storing this information in a non-volatile memory. After collecting and storing the information, the system assesses the daily exposure of a person to electromagnetic radiation.
The contraceptive pill may be the answer for sports women who are prone to knee injuries, according to a Australian study.
› Verified 1 days ago